Colfax Reports First Quarter 2017 Results Annapolis

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
56
Colfax Reports First Quarter 2017 Results

Annapolis Junction, MD, May 05, 2017 (GLOBE NEWSWIRE) --

  • Achieved first quarter net income per diluted share of $0.31 and adjusted net income per share of $0.35
  • Delivered Fabrication Technology organic revenue growth and third consecutive quarter of Gas and Fluid Handling order growth
  • Grew operating income by 37% and adjusted operating income by 11%
  • Improved full year outlook

Colfax Corporation (NYSE: CFX), a leading global manufacturer of gas and fluid handling and fabrication technology products and services, today announced its financial results for the first quarter of 2017.

For the first quarter of 2017, net income was $38.5 million, or $0.31 per diluted share, compared to $22.6 million, or $0.18 per diluted share, for the first quarter of 2016. Adjusted net income was $43.7 million, or $0.35 per share for the first quarter of 2017, compared to $36.9 million, or $0.30 per share for the first quarter of 2016.

The Company reported first quarter net sales of $844.9 million, compared with $876.8 million in the first quarter of 2016. The decrease included a marginal decline from foreign currency exchange rates, an approximate 1% increase from acquisitions, and 1.1% organic growth in the Company’s Fabrication Technology segment, which partially offset the expected decline in gas and fluid handling sales.

First quarter operating income was $66.2 million or 7.8% of sales, and adjusted operating income was $73.3 million or 8.7% of sales. The prior year first quarter operating income was $48.5 million or 5.5% of sales, and the adjusted operating income was $66.1 million or 7.5% of sales.

“We are pleased to announce strong first quarter results in a more constructive market environment,” said Matthew Trerotola, President and Chief Executive Officer. “The 120 basis point improvement in our adjusted operating margins reflects ongoing work to create a more competitive cost structure and customer-focused organization. Our Gas and Fluid Handling segment delivered its third straight quarter of orders growth, achieving double digit organic growth for the first time in more than three years. Our Fabrication Technology segment organically grew revenues due to improved market conditions in most regions and notably strong performance by our teams in Europe, Russia, China and India.”

“Over the last few months, we also made progress on the longer-term agenda. We announced the acquisition of Siemens Turbomachinery Equipment, which will strengthen and expand our air handling solutions, and we continue to see a robust pipeline of acquisition opportunities to build on our existing businesses. We also completed a successful senior note offering, locking in attractive long term interest rates.”

Considering the improved end market conditions and the recently concluded notes offering, Colfax revised its outlook for the year, increasing its earnings per share forecast from $1.29-$1.44 to $1.34-$1.49, and its adjusted earnings per share forecast from $1.55-$1.70 to $1.60-$1.75. This outlook does not include the effects, if any, from the acquisition of Siemens Turbomachinery Equipment, which is expected to close in the fourth quarter of 2017.

Conference Call and Webcast

Colfax will host a conference call to provide details about its results on Friday, May 5, 2017 at 9:00 a.m. EDT. The call will be open to the public through 877-303-7908 (U.S. callers) or 678-373-0875 (international callers) and referencing the conference ID number 11652919, or through webcast via Colfax’s website at www.colfaxcorp.com under the “Investors” section. Access to a supplemental slide presentation can also be found at the Colfax website under the same heading. Both the audio of this call and the slide presentation will be archived on the website later today and will be available until the next quarterly call.

About Colfax Corporation

Colfax Corporation is a diversified global manufacturing and engineering company that provides gas and fluid handling and fabrication technology products and services to commercial and governmental customers around the world through the Howden, Colfax Fluid Handling and ESAB businesses. Colfax believes that its brands are among the most highly recognized in each of the markets that it serves. Colfax is traded on the NYSE under the ticker “CFX.” Additional information about Colfax is available at www.colfaxcorp.com.

Non-GAAP Financial Measures and Other Adjustments

Colfax has provided in this press release financial information that has not been prepared in accordance with GAAP. These non-GAAP financial measures are adjusted net income, adjusted net income per share, projected adjusted net income per share, adjusted operating income, adjusted operating income margin, organic sales decline and organic order growth. Adjusted net income, adjusted net income per share, projected adjusted net income per share, adjusted operating income and adjusted operating income margin exclude Restructuring and other related charges. The effective tax rates used to calculate adjusted net income and adjusted net income per share are 27.4% for the three months ended March 31, 2017 and 29.0% for the three months ended April 1, 2016. Organic sales decline and organic order growth exclude the impact of acquisitions and foreign exchange rate fluctuations. These non-GAAP financial measures assist Colfax in comparing its operating performance on a consistent basis because, among other things, they remove the impact of restructuring and other related charges.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of non-GAAP financial measures presented above to GAAP results has been provided in the financial tables included in this press release.

CAUTIONARY NOTE CONCERNING FORWARD LOOKING STATEMENTS:

This press release may contain forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Colfax’s plans, objectives, expectations and intentions and other statements that are not historical or current fact. Forward-looking statements are based on Colfax’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Colfax’s results to differ materially from current expectations include, but are not limited to factors detailed in Colfax’s reports filed with the U.S. Securities and Exchange Commission including its 2016 Annual Report on Form 10-K under the caption “Risk Factors.” In addition, these statements are based on a number of assumptions that are subject to change. This press release speaks only as of the date hereof. Colfax disclaims any duty to update the information herein.

The term “Colfax” in reference to the activities described in this press release may mean one or more of Colfax’s global operating subsidiaries and/or their internal business divisions and does not necessarily indicate activities engaged in by Colfax Corporation.

Colfax Corporation Condensed Consolidated Statements of Income Dollars in thousands, except per share data (Unaudited)

 Three Months Ended
 March 31, 2017 April 1, 2016
    
Net sales$844,926  $876,843 
Cost of sales565,559  596,322 
Gross profit279,367  280,521 
Selling, general and administrative expense206,046  214,387 
Restructuring and other related charges7,100  17,668 
Operating income66,221  48,466 
Interest expense9,095  9,120 
Income before income taxes57,126  39,346 
Provision for income taxes15,639  13,136 
Net income41,487  26,210 
Less: income attributable to noncontrolling interest, net of taxes2,945  3,595 
Net income attributable to Colfax Corporation$38,542  $22,615 
Net income per share - basic and diluted$0.31  $0.18 

Colfax Corporation Reconciliation of GAAP to Non-GAAP Financial Measures Dollars in thousands, except per share data (Unaudited)

 Three Months Ended
 March 31, 2017 April 1, 2016
Adjusted Operating Income   
Operating income$66,221  $48,466 
Operating income margin7.8% 5.5%
Restructuring and other related charges7,100  17,668 
Adjusted operating income$73,321  $66,134 
Adjusted operating income margin8.7% 7.5%
 Three Months Ended
 March 31, 2017 April 1, 2016
Adjusted Net Income and Adjusted Net Income Per Share   
Net income attributable to Colfax Corporation$38,542  $22,615 
Restructuring and other related charges7,100  17,668 
Tax adjustment(1)(1,959) (3,398)
Adjusted net income$43,683  $36,885 
Adjusted net income margin5.2% 4.2%
Weighted-average shares outstanding - diluted123,795  123,243 
Adjusted net income per share$0.35  $0.30 
Net income per share— diluted (in accordance with GAAP)$0.31  $0.18 

__________

(1) The effective tax rate used to calculate adjusted net income and adjusted net income per share was 27.4% for the three months ended March 31, 2017 which includes a $0.9 million discrete tax benefit primarily associated with a South American jurisdiction. The effective tax rate used to calculate adjusted net income and adjusted net income per share for the three months ended April 1, 2016 was 29.0%.

 2017 Earnings Per Share Range
Projected net income per share - diluted$1.34  $1.49 
Restructuring costs0.36  0.36 
Tax adjustment(0.10) (0.10)
Projected adjusted net income per share$1.60  $1.75 

Colfax Corporation Change in Sales, Orders and Backlog Dollars in millions (Unaudited)

     Gas and Fluid Handling
 Net Sales Orders Backlog at Period End
 $ % $ % $ %
            
As of and for the three months ended April 1, 2016$876.8    $406.3    $1,135.3   
Components of Change:           
Existing Businesses(1)(35.6) (4.1)% 46.6  11.5% (7.5) (0.7)%
Acquisitions(2)6.5  0.7% —  —% —  —%
Foreign Currency Translation(2.8) (0.2)% (7.7) (1.9)% (43.1) (3.8)%
 (31.9) (3.6)% 38.9  9.6% (50.6) (4.5)%
As of and for the three months ended March 31, 2017$844.9    $445.2    $1,084.7   

__________

(1) Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of growth due to factors such as price, product mix and volume. (2) Represents the incremental sales as a result of our acquisition of Arc Machines, Inc. (“AMI”).

Fabrication Technology Net Sales
  $ %
     
For the three months ended April 1, 2016 $444.1   
Components of Change:    
Existing Businesses(1) 4.7  1.1%
Acquisitions(2) 6.5  1.4%
Foreign Currency Translation 4.7  1.1%
  15.9  3.6%
For the three months ended March 31, 2017 $460.0   

__________

(1) Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of growth due to factors such as price, product mix and volume. (2) Represents the incremental sales as a result of our acquisition of AMI.

Contact: Terry Ross, Vice President of Investor Relations Colfax Corporation 301-323-9054 Terry.Ross@colfaxcorp.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

Updated Category News Views 218

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 298

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 160

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 159

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 61

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
MV Transportation Celebrates Leadership Nomination for FTA

Updated Category News Views 225

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 126

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 321

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 273

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 28

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading

Top 5 Most Recently Viewed Articles

McKinney's New Consumer PR Practice Sparks Marketing Buzz

Updated Category News Views 217

Market Dynamics Shifting: McKinney's Bold Move Let’s cut to the chase: McKinney’s launching a consumer PR practice—big deal, right? Well, hold your horses. This ain't just another agency spitting out press releases. They’re bringing in Jae Siercks, a heavy hitter from Weber Shandwick, to lead the charge. This kind of strategy echoes back to the days of the dot-com...

Continue Reading
Pariveda's Commitment: Winning Social Impact Partner Award

Updated Category News Views 218

Pariveda Recognized as Social Impact Partner of the Year Pariveda is proud to announce its recognition as the winner of the 2025 Geography and Global AWS Partner Award, highlighting its significant role as an innovator in the technology space. This prestigious award showcases the dedication of AWS Partners worldwide in advancing solutions using Amazon Web Services (AWS)....

Continue Reading
Eric A. Seiff: Celebrated Advocate in Criminal Defense for 2024

Updated Category News Views 179

Back in 2024, Eric A. Seiff was recognized among America’s Top 100 Criminal Defense Attorneys—a title only given to the absolute cream of the crop, with fewer than 0.5% of practicing attorneys making the cut. You gotta appreciate that level of distinction; it ain't just about being good—it’s about years spent fighting tooth and nail for what’s right in a...

Continue Reading
Wells Fargo Raises Price Target for Morgan Stanley Stock

Updated Category News Views 147

Wells Fargo Adjusts Morgan Stanley's Stock Outlook Recently, Wells Fargo reviewed its stance on Morgan Stanley (NYSE: MS), increasing the price target from $95.00 to $107.00. While this adjustment is a positive sign, the firm decided to keep an Underweight rating on the stock. The increase in the price target comes after Morgan Stanley's performance in the third quarter,...

Continue Reading
Raytone Biotech Begins RTP-008 Clinical Trial for Dry Eye Relief

Updated Category News Views 218

Raytone Biotech Begins RTP-008 Clinical Trial for Dry Eye Relief Raytone Biotech, a clinical-stage biotechnology company focused on innovative ophthalmic therapies, recently achieved a significant milestone by successfully completing the first patient dosing in its clinical trial for RTP-008. This new therapy is purposefully designed for those suffering from dry eye...

Continue Reading